Bausch & Lomb logo
Home
Facebook
Twitter
Linkedin
Summary:
COMPANY:​
Bausch & Lomb
INDUSTRIES:​
Health Care
HEADQUARTERS:​
Rochester, New York, United States
ABOUT:
Bausch + Lomb is the eye health company dedicated to Bringing Visionary Ideas to Eye Health.
STOCK SYMBOL:
:
IPO STATUS:
Private
Bausch + Lomb is the eye health company dedicated to Bringing Visionary Ideas to Eye Health. They offer the world’s most comprehensive portfolio of eye health products, and They have one of the oldest, best known and most respected healthcare brands in the world. The company began in 1853 in Rochester, New York, as a small optical shop that grew to become a multi-billion dollar corporation with approximately 13,000 employees worldwide, and with products available in more than 100 countries.
POWERED BY CRUNCHBASE
Financials:
FUNDING (USD):​
STATUS:
For Profit
INVESTORS:​
TOP 5 INVESTORS:​
FOUNDERS:​
Bernard Chauvin
LAST LEADERSHIP HIRE:
EMPLOYEES:
1001-5000
ACQUISITIONS​:

YouTube

Bausch and Lomb

We are a leading global eye health organization that is solely focused on helping people see better to live better. Our core businesses include over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. We develop, manufacture and market one of the most comprehensive product portfolios in the industry, which is available in more than 100 countries.

Bausch and Lomb
Learn more about flexible dosing with BESIVANCE® (besifloxacin ophthalmic suspension 0.6%), formulated with DuraSite® technology. A flexible dosing schedule with BESIVANCE may be particularly convenient for pediatric patients age 1 and up and their families. Ask your child’s doctor about BESIVANCE today and save on your prescription by going to https://www.bauschaccessprogram.com/. Approved for children ages 1 and older. INDICATION BESIVANCE® (besifloxacin ophthalmic suspension) 0.6% is a fluoroquinolone antibacterial medicine used to treat an infection of the eye called bacterial conjunctivitis, caused by certain types of germs called bacteria. Contact your doctor for more information about this type of eye infection or the bacteria that cause it. IMPORTANT SAFETY INFORMATION • To avoid contamination of the bottle tip, do not touch the bottle tip with material from your eye, your fingers or other source. Wash hands thoroughly before using BESIVANCE • Do not wear contact lenses while using BESIVANCE or any time you have signs or symptoms of an eye infection. • Before each use, turn the BESIVANCE bottle upside down and shake once. While upside down, remove cap, tilt head back and gently squeeze bottle to put in one drop into the affected eye(s). • The most common side effect reported in clinical studies was eye redness in approximately 2% of patients. Other side effects reported in approximately 1-2% of patients were blurred vision, eye pain, eye irritation, itchy eye and headache. • Safety and effectiveness in infants below one year of age have not been established. • Not for injection into the eye. Please see full Prescribing Information for BESIVANCE at https://www.bausch.com/Portals/69/-/m/BL/United%20States/USFiles/Package%20Inserts/Pharma/Besivance-Full-Prescribing-Info.pdf. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit https://www.fda.gov/medwatch or call 1-800-FDA-1088. BESIVANCE is a registered trademark of Bausch & Lomb Incorporated or its affiliates. DuraSite is a trademark of Sun Pharma Global FZE used by permission. © 2020 Bausch & Lomb Incorporated or its affiliates. Created in the USA. All rights reserved. 09/20. BES.0042.USA.20
Dosing with BESIVANCE® (besifloxacin ophthalmic suspension 0.6%) and DuraSite® Technology
YouTube Video UCrNOI0r-5Dst-V3ZF72Whxg_fEJH-dK0Xr4
IMPORTANT SAFETY INFORMATION • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent • Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation • Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation • Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema • There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients • Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration • Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%) INDICATION VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. PLEASE SEE FULL PRESCRIBING INFORMATION AT: https://bit.ly/2DZizSA Watch optometrists discuss why long-term safety matters for their open-angle glaucoma patients and the compelling safety data from VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% clinical trials. See the full safety profile from Phase 3 trials and request samples at https://www.vyzultahcp.com/clinical-studies. VYZULTA and the V design are trademarks of Bausch & Lomb Incorporated or its affiliates. ©2020 Bausch & Lomb Incorporated or its affiliates. All rights reserved. VYZ.0167.USA.20
Why Are Low Hyperemia And Adherence So Important In Glaucoma?
YouTube Video UCrNOI0r-5Dst-V3ZF72Whxg_IDsFKJ1Za5I
IMPORTANT SAFETY INFORMATION • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent • Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation • Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation • Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema • There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients • Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration • Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%) INDICATION VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. PLEASE SEE FULL PRESCRIBING INFORMATION AT: https://bit.ly/2DZizSA Find out how VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% performed across a variety of open-angle glaucoma and ocular hypertension patients in clinical trials. Explore the efficacy and safety data and request samples at https://www.vyzultahcp.com/clinical-studies. VYZULTA and the V design are trademarks of Bausch & Lomb Incorporated or its affiliates. ©2020 Bausch & Lomb Incorporated or its affiliates. All rights reserved. VYZ.0167.USA.20
VYZULTA Clinical Trial Results | See What Stood Out To These ODs
YouTube Video UCrNOI0r-5Dst-V3ZF72Whxg_1cowrzq35bY
IMPORTANT SAFETY INFORMATION • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent • Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation • Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation • Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema • There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients • Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration • Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%) INDICATION VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. PLEASE SEE FULL PRESCRIBING INFORMATION AT: https://bit.ly/2DZizSA Watch eye care professionals share why VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% is their go-to choice for appropriate mild-to-moderate open-angle glaucoma patients. Find out why VYZULTA may be the right fit for your patients and request samples at https://www.vyzultahcp.com/clinical-studies. VYZULTA and the V design are trademarks of Bausch & Lomb Incorporated or its affiliates. ©2020 Bausch & Lomb Incorporated or its affiliates. All rights reserved. VYZ.0167.USA.20
Who Is Right For VYZULTA? Optometrists Share Their Opinions
YouTube Video UCrNOI0r-5Dst-V3ZF72Whxg_EU4VVz5Y2n8
IMPORTANT SAFETY INFORMATION • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent • Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation • Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation • Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema • There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients • Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration • Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%) INDICATION VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. PLEASE SEE FULL PRESCRIBING INFORMATION AT: https://bit.ly/2DZizSA Watch optometrists discuss how VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% works differently to reduce intraocular pressure (IOP) and why it matters. VYZULTA isn’t your typical prostaglandin analog (PGA). Get the details and find out how you can request samples to see VYZULTA in action at https://www.vyzultahcp.com/iop-regulation. VYZULTA and the V design are trademarks of Bausch & Lomb Incorporated or its affiliates. ©2020 Bausch & Lomb Incorporated or its affiliates. All rights reserved. VYZ.0167.USA.20
Discover Dual-Mechanism IOP Reduction From A Novel PGA
YouTube Video UCrNOI0r-5Dst-V3ZF72Whxg_JVO2KLYfZrQ
Load More... Subscribe

Bausch + Lomb Japan

ボシュロムのYouTube公式チャンネルです。CM等、最新の動画を公開しています。

コンタクトレンズやケア用品など製品情報、無料体験クーポン、製品取扱い施設の検索はボシュロム・ウェブサイトをご覧ください。

Bausch + Lomb Japan
きれいに洗ったつもりでも、コンタクトレンズには菌が残っていることも…。温泉で元気にはしゃぐレンズ菌！見えてしまったあなたは要注意！？レニューは、売上 No.1※！消毒力でレンズ菌を撃退！そのすぐれた消毒力の秘密とは？ https://renu.jp/lens-kin-special 医薬部外品＜ソフトコンタクトレンズ用消毒剤＞ ＜販売名：レニュー マルチプラス®︎＞＜販売名：レニュー®＞ ※（株）インテージSDI コンタクトレンズケア剤MPS市場 2009年1月～2019年12月 各年間累計販売金額　レニューブランド合計
レンズ菌、放置してない？「レンズ菌の温泉旅行」篇
YouTube Video UCe2PJe_V0U0AufZZfJvLU4w_zNgPBFM6kSc
「当たり前って、むずかしい」 ▼出演 バレーボール 柳田将洋選手 フェンシング／近代五種 才藤歩夢選手 第一線で活躍するアスリートが日々当たり前に取り組んでいることを通して、コンタクトレンズの正しい使い方やケアを積み重ねることの大切さをお伝えします。 ▼特設サイトで本編公開中 https://bauschlomb.jp/staysafe/ #ボシュロム #コンタクトレンズ #staysafe #当たり前ってむずかしい #柳田将洋 #才藤歩夢 #バレーボール #近代五種 #フェンシング
「当たり前って、むずかしい」30秒 柳田将洋／才藤歩夢
YouTube Video UCe2PJe_V0U0AufZZfJvLU4w_cBTIa6wqc-M
「当たり前って、むずかしい バレーボール 柳田将洋選手篇」 第一線で活躍するアスリートが日々当たり前に取り組んでいることを通して、コンタクトレンズの正しい使い方やケアを積み重ねることの大切さをお伝えします。 ▼特設サイトでWEBムービー公開中 https://bauschlomb.jp/staysafe/ #ボシュロム #コンタクトレンズ #staysafe #当たり前ってむずかしい #柳田将洋 #バレーボール
「当たり前って、むずかしい」バレーボール 柳田将洋選手篇 70秒
YouTube Video UCe2PJe_V0U0AufZZfJvLU4w_bwMmNZmQUJA
「当たり前って、むずかしい フェンシング／近代五種 才藤歩夢選手篇」 第一線で活躍するアスリートが日々当たり前に取り組んでいることを通して、コンタクトレンズの正しい使い方やケアを積み重ねることの大切さをお伝えします。 ▼特設サイトでWEBムービー公開中 https://bauschlomb.jp/staysafe/ #ボシュロム #コンタクトレンズ #staysafe #当たり前ってむずかしい #才藤歩夢 #近代五種 #フェンシング
「当たり前って、むずかしい」フェンシング／近代五種 才藤歩夢選手篇 67秒
YouTube Video UCe2PJe_V0U0AufZZfJvLU4w__t3qokx0Gjw
「当たり前って、むずかしい バレーボール 柳田将洋選手篇」 メイキングムービーを公開！ ▼特設サイトでWEBムービー公開中 https://bauschlomb.jp/staysafe/ #ボシュロム #コンタクトレンズ #staysafe #当たり前ってむずかしい #柳田将洋 #バレーボール
「当たり前って、むずかしい」バレーボール 柳田将洋選手篇 メイキングムービー 120秒
YouTube Video UCe2PJe_V0U0AufZZfJvLU4w_1xiMUQ4Yn4U
Load More... Subscribe

Twitter

Bausch + Lomb
Bausch + Lomb

@Smittttten Hello @Smittttten — Please reach out to our consumer affairs department Monday - Friday 9-5 EST at 1-80… https://t.co/006HN6G2PT

Bausch + Lomb
Bausch + Lomb

@Gisele_Human Please note that the recycling symbol is embedded on all of our contact lens solution bottles and len… https://t.co/lT17PxAuBN

Bausch + Lomb
Bausch + Lomb

@Gisele_Human Hello — Contact lens cases can be a source of bacteria growth, which is why it is recommended to

Bausch + Lomb
Bausch + Lomb

Our SimplifEYE™ intraocular lens (IOL) delivery system, which is exclusively available for the enVista® MX60PL and… https://t.co/KzFMoP7MFI

Bausch + Lomb
Bausch + Lomb

Our ONE by ONE Recycling Program is featured on the cover of #BauschHealth (our parent company’s) CSR report this y…

Bausch + Lomb
Bausch + Lomb

@Ayrin_Ferguson We apologize for the inconvenience and are working diligently with our suppliers to make the produc… https://t.co/OWMhSc4T3P

Tokyo Office:

B.LJ Company Ltd.
Tower B, Omori Bellport 7 Fl
6-26-2, Minami-Oi, Shinagawa
Tokyo 140-0013, Japan

Tagged